According to the WHO, malaria affected 229 million people worldwide in 2019, resulting in 409,000 deaths. Timely access to appropriate treatment is key to ensuring a bout of acute uncomplicated malaria does not turn into a severe case.
Eurartesim protects patients from new malaria infections for an extended period
Eurartesim is a fixed-dose combination of dihydroartemisinin-piperaquine (DHA-PQP), developed by Alfasigma S.p.A. in partnership with MMV, for the treatment of acute uncomplicated P. falciparum malaria. Eurartesim is administered once a day over 3 days. Studies have shown that Eurartesim’s long half-life affords patients a useful period of protection from new malaria infections.1
An essential medicine recommended by WHO
In October 2011, the European Medicines Agency (EMA) granted marketing authorization for Eurartesim. In October 2015, Eurartesim was prequalified by WHO and, in June 2017, DHA-PQP was added to WHO’s Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc) after a successful application to the EML by Alfasigma.
Eurartesim is available in 32 African countries
In 2015, Alfasigma entered into an exclusive licensing agreement with Pierre Fabre to expand its ability to support country registration requirements and national adoption of Eurartesim in 32 African countries. Over 4.5 million treatments of Eurartesim have been distributed since approval by the EMA.
Alfasigma will submit a regulatory dossier to the EMA for a new dispersible formulation of Eurartesim designed specifically to address the treatment needs of children.